apl. Prof. Dr. Luitpold Distel

Einrichtungen, die zum Universitätsklinikum Erlangen gehören Medizinische Fakultät Department of Radiation Oncology

Combination of growth pattern and tumor regression identifies a high-risk group in neoadjuvant treated rectal cancer patients (2017) Jeßberger J, Erlenbach-Wuensch K, Posselt R, Haderlein M, Agaimy A, Fietkau R, Hartmann A, Distel L Journal article Tumor infiltrating cells - cell-to-cell distances enable differentiation between functionally active and suppressed inflammatory cells (2016) Distel L, Nagl S, Fietkau R, Haas M Conference contribution Oxidized silicon nanoparticles and iron oxide nanoparticles for radiation therapy (2016) Klein S, Kizaloglu M, Dell'Acriprete ML, Neuhuber W, Distel L, Gonzales MC, Kryschi C Conference contribution Targeted next-generation sequencing identifies molecular subgroups in squamous cell carcinoma of the head and neck with distinct outcome after concurrent chemoradiation (2016) Tinhofer I, Stenzinger A, Eder T, Konschak R, Niehr F, Endris V, Distel L, et al. Journal article Ex Vivo Apoptosis in CD8+ Lymphocytes Predicts Rectal Cancer Patient Outcome (2016) Winkler S, Hoppe P, Haderlein M, Hecht M, Fietkau R, Distel L Journal article Spatial distribution of FoxP3+ and CD8+ tumour infiltrating T cells reflects their functional activity (2016) Posselt R, Erlenbach-Wuensch K, Haas M, Jeßberger J, Buettner-Herold M, Haderlein M, Hecht M, et al. Journal article Feasibility of a 12-month-exercise intervention during and after radiation and chemotherapy in cancer patients: impact on quality of life, peak oxygen consumption, and body composition (2016) Grabenbauer A, Grabenbauer AJ, Lengenfelder R, Grabenbauer GG, Distel L Journal article PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosis (2016) Hecht M, Buettner-Herold M, Erlenbach-Wuensch K, Haderlein M, Croner R, Grützmann R, Hartmann A, et al. Journal article Cell-to-cell distances between tumor-infiltrating inflammatory cells have the potential to distinguish functionally active from suppressed inflammatory cells (2016) Nagl S, Haas M, Lahmer G, Buettner-Herold M, Grabenbauer G, Fietkau R, Distel L Journal article Efavirenz Has the Highest Anti-Proliferative Effect of Non-Nucleoside Reverse Transcriptase Inhibitors against Pancreatic Cancer Cells (2015) Hecht M, Erber S, Harrer T, Klinker H, Roth T, Parsch H, Fiebig N, et al. Journal article